Saturday, July 13, 2024

Cost-Effectiveness of Buprenorphine Buccal Film vs. Transdermal Patches in Chronic Low Back Pain Management

Similar articles

The economic burden and prescribing trends for chronic low back pain (cLBP) patients treated with buprenorphine buccal film (Belbuca®) compared to transdermal patches have been evaluated in a new study. Utilizing data from MarketScan® commercial insurance claims from 2018 to 2021, the research focused on the first prescription date as the index event, assessing healthcare expenditures, cost trends, and resource utilization over a 6-month pre-index and a 12-month post-index period.

Methodology and Study Design

The study included patients who were propensity-score matched, with 708 patients in each cohort. Researchers examined the economic and clinical outcomes associated with buprenorphine buccal film and transdermal patches. The analysis revealed that the initiation of buprenorphine showed stable cost trends for the buccal film cohort, while the transdermal patch cohort experienced increasing cost trends. This differentiation in cost trends is significant for market access considerations, as it highlights the potential for more predictable budgeting with buccal films.

Key Findings and Economic Implications

The study’s results indicated that buprenorphine buccal film not only had a more favorable cost profile but also demonstrated higher daily doses and a wider dosing range compared to transdermal patches. This flexibility in prescribing can enhance patient adherence and satisfaction, making buccal films a more attractive option for healthcare providers and payers. Additionally, the between-cohort comparisons showed significant differences in healthcare expenditures and resource utilization, largely favoring buccal film.

Actionable Insights

– Healthcare providers should consider buprenorphine buccal film for its cost-effectiveness and flexible dosing.
– Insurers may benefit from encouraging the use of buccal film to manage long-term expenditures.
– Policymakers should note the economic advantages when forming guidelines for cLBP treatments.

These insights underscore the importance of evaluating both clinical efficacy and economic impact when assessing market access for new treatments. The study concludes that buprenorphine buccal film presents a more cost-effective treatment option for chronic low back pain, with significant advantages in terms of dosing flexibility and economic burden.

Original Article:

Pain Manag. 2024;14(4):195-207. doi: 10.1080/17581869.2024.2348989. Epub 2024 May 31.

You can follow our news on our Telegram and LinkedIn accounts.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article